June 27, 2024

Markets continued to drift as investors stay on the sideline ahead of key inflation data due out on Friday US time. The S&P 500 just managed to finish in positive territory closing up 0.09 per cent. The Nasdaq closed 0.30 per cent higher, while the Dow Jones closed 0.09 per cent higher. Turning to US […]

Job vacancy data for May support explanations about the continuing strength of the Australian labour market. Data released Thursday by the Australian Bureau of Statistics show there were 352,700 job vacancies in May 2024, down 10,000 from February, a fall of 2.7%. This followed a fall of 6.2% in February 2024. The ABS said that

Southern Cross Media Group (ASX:SXL) has walked away from the attempt by the unlisted Australian Community Media to rid itself of some of the biggest regional newspapers in Australia. The titles include The Newcastle Herald, Canberra Times, Illawarra Mercury, and two major papers in Tasmania, as well as smaller titles in NSW and Victoria, plus

The US Federal Reserve has given the country’s biggest banks, including some big regionals and credit card operators, a clean bill of health in its latest stress tests. The tests, conducted earlier this year, found that the banks would be able to withstand a severe recession scenario while maintaining their ability to lend to consumers

At 11:30am, the S&P/ASX 200 is 1.18 per cent lower at 7,690.90, following inflation data that exceeded expectations, showing a 4 per cent increase for the year to May. In contrast, shares in New York rose, driven by gains in tech stocks such as Apple, Amazon, and Tesla, while Nvidia ended modestly higher and Micron

Lynas (ASX:LYC) is going to spend around $US25 million adding a new stream of rare earth products to the range produced at its Malaysian operation. In a statement to the ASX on Thursday, Lynas said the processing circuits at the Malaysian operation will be modified to produce two new separated Heavy Rare Earth (HRE) products

Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific Officer Professor Frédéric Triebel, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results. Key points:Efti in combination with KEYTRUDA® (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC) led to